No Data
No Data
BioAge Stock Rallies 29% Following Upsized $198M IPO
RBC Capital Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $362
Dow, S&P 500 Retreat From Record Highs
Amgen Stock Slides 5% as Analysts Weigh in on Drug Study Results
Amgen Stock Slips 3% Following Phase 3 Data for Rocatinlimab, Uplizna
Analyst Expectations For Amgen's Future
ひな☆彡 SOXL : You convinced me. I am happy to buy some later.
Growth Investor27 : Long ESPR $1.61 is very cheap.
Growth Investor27 : Long150,000 will hold for 5x upside for 2025 if not aquired.